{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-022753","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.469618+00:00","generated_at":"2026-05-22T10:44:40.778624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cumberland Q1 revenue $11.7M (+38% YoY), net profit $1.3M; DMD Phase II positive, Vibativ China OK","bullets":["Net revenue $11.7M vs $8.5M prior year, 38% increase.","Net income $1.3M; adjusted earnings $2.4M ($0.16/shr); operating cash flow $3.9M.","Positive Phase II data for ifetroban in Duchenne muscular dystrophy; FDA end-of-phase-II meeting planned.","Vibativ approved in China; launch expected by end of 2025.","Balance sheet: $15.1M cash, $5.2M drawn on credit facility; equity $28.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-022753","json":"https://secwatch.observer/filing/0001628280-25-022753.json","markdown":"https://secwatch.observer/filing/0001628280-25-022753.md","text":"https://secwatch.observer/filing/0001628280-25-022753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/0001628280-25-022753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025022753/cpix-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:44:40.778624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}